Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 20Carcinoma, Renal Cell 10Neuroendocrine Tumors 7Neoplasm Metastasis 7Recurrence 4Tuberous Sclerosis 3Triple Negative Breast Neoplasms 3Neoplasms 3Kidney Neoplasms 3Endometrial Neoplasms 3von Hippel-Lindau Disease 2Skin Neoplasms 2Sarcoma 2Meningioma 2Glioma 2Gastro-enteropancreatic neuroendocrine tumor 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Adenoma, Islet Cell 2Waldenstrom Macroglobulinemia 1Vascular Malformations 1Unilateral Breast Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Thymus Neoplasms 1Seizures 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1

Interventions

fludarabine 52Cyclophosphamide 50venetoclax 47Azacitidine 44fludarabine phosphate 41Whole-Body Irradiation 33Specimen Handling 31Mycophenolic Acid 30Tacrolimus 28Melphalan 28Busulfan 27Cytarabine 25Stem Cell Transplantation 23Decitabine 23Biopsy 22Granulocyte Colony-Stimulating Factor 19Sirolimus 16Peripheral Blood Stem Cell Transplantation 16Filgrastim 16Thiotepa 15decitabine and cedazuridine drug combination 14Injections 13Cyclosporine 13ruxolitinib 9Methotrexate 9Mesna 9Hematopoietic Stem Cell Transplantation 9X-Rays 8Idarubicin 8Daunorubicin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Everolimus × 1 year × Clear all
NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡